ICER releases draft evidence report on cost effectiveness of myasthenia gravis treatments
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - August 1, 2021 Category: Drugs & Pharmacology Source Type: news

Durvalumab-induced Myocarditis, Myositis, and Myasthenia Gravis Durvalumab-induced Myocarditis, Myositis, and Myasthenia Gravis
This case reviews the diagnostic workup and management of a patient with severe immune-related adverse effects due to the immune checkpoint inhibitor durvalumab.Journal of Medical Case Reports (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - July 1, 2021 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

Potential First-in-Class, Targeted Therapy for Myasthenia Gravis Potential First-in-Class, Targeted Therapy for Myasthenia Gravis
Efgartigimod is linked to clinically meaningful improvements in strength and quality of life in patients with generalized myasthenia gravis, the phase 3 ADAPT trial shows.Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - June 18, 2021 Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news

What Are Some Indications for Using Dexamethasone?
Discussion Corticosteroids are a group of drugs which can be naturally or synthetically produced. Naturally occurring substances are produced in the adrenal gland, and are protein-bound (primarily corticosteroid-binding globulin and albumin). In the target tissues, they may need to be converted to an active substance. They are then reduced, oxidized, hydroxylated or conjugated as measures to inactivate them. Synthetic steroids have less protein binding and depending on their structure are more or less resistant to inactivation. Prednisone is the glucocorticoid most often used for treatment, especially as it has a short hal...
Source: PediatricEducation.org - June 7, 2021 Category: Pediatrics Authors: Pediatric Education Tags: Uncategorized Source Type: news

Pembrolizumab-induced Myasthenia Gravis-like Disorder Pembrolizumab-induced Myasthenia Gravis-like Disorder
This case suggests that concomitant use of low-dose steroids and pembrolizumab might prevent neurocomplications of checkpoint inhibitor therapy.Journal of Medical Case Reports (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 20, 2021 Category: Consumer Health News Tags: Family Medicine/Primary Care Journal Article Source Type: news

New Steroid Dosing Regimen for Myasthenia Gravis New Steroid Dosing Regimen for Myasthenia Gravis
The use of a new rapid tapering regimen resulted in a lower cumulative dose of prednisone with similar clinical outcomes in a new randomized study.Medscape Medical News (Source: Medscape Pharmacist Headlines)
Source: Medscape Pharmacist Headlines - February 16, 2021 Category: Drugs & Pharmacology Tags: Neurology & Neurosurgery News Source Type: news

What Causes Lethargy?
Discussion Lethargy is a common word used to describe a person who is drowsy, sluggish, listless and apathetic. Concentration may be difficult and they may have problems doing simple tasks. Many people actual mean fatigue or lassitude or being more tired when they use the word. In medical terms, lethargy is usually used to describe patients who have some type of excessive tiredness and usually have mental status changes with decreased alertness or arousal. Patients and health care providers both usually qualify the term and give more description to better communicate what is implied when using the term. This is true of man...
Source: PediatricEducation.org - January 25, 2021 Category: Pediatrics Authors: Pediatric Education Tags: Uncategorized Source Type: news

Ocular Side Effects Possible With Checkpoint Inhibitors Ocular Side Effects Possible With Checkpoint Inhibitors
People who use immune-checkpoint inhibitors have an increased risk of noninfectious uveitis and myasthenia gravis, according to a database study.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 27, 2020 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Janssen Headlines American Society of Hematology Annual Meeting With More Than 35 Presentations Highlighting Deep, Diverse Oncology Pipeline and Portfolio
RARITAN, N.J., November 5, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today more than 35 company-sponsored studies, including 10 oral presentations, will be featured at the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition taking place virtually December 5-8, 2020.In multiple myeloma, highlights include Phase 1b/2 results for the B-cell maturation antigen (BCMA)-targeted chimeric antigen receptor T-cell (CAR-T) therapy ciltacabtagene autoleucel (cilta-cel); new and updated data for the anti-CD38 monoclonal antibody DARZALEX® (daratumumab) and the subcutane...
Source: Johnson and Johnson - November 5, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news

COVID-19 Linked to Development of Myasthenia Gravis COVID-19 Linked to Development of Myasthenia Gravis
Three patients with no prior neurologic or autoimmune disorders developed myasthenia gravis within a week after onset of fever from SARS-CoV-2 infection.Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - August 19, 2020 Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news

Johnson & Johnson to Acquire Momenta Pharmaceuticals, Inc., Expanding Janssen ’s Leadership in Novel Treatments for Autoimmune Diseases
NEW BRUNSWICK, N.J., August 19, 2020 – Johnson & Johnson (NYSE:JNJ) today announced it has entered into a definitive agreement to acquire Momenta Pharmaceuticals, Inc. (Momenta), a company that discovers and develops novel therapies for immune-mediated diseases, in an all cash transaction for approximately $6.5 billion. This acquisition provides an opportunity for the Janssen Pharmaceutical Companies of Johnson & Johnson to broaden its leadership in immune-mediated diseases and drive further growth through expansion into autoantibody-driven disease. The transaction will include full global rights to nipocalim...
Source: Johnson and Johnson - August 19, 2020 Category: Pharmaceuticals Tags: Our Company Source Type: news

Patients with recently discovered antibodies have more severe myasthenia gravis
(Medical College of Georgia at Augusta University) A study of 181 patients at 16 sites across the country who test negative for two antibodies long known to cause muscle-weakening myasthenia gravis, found that about 15% test positive for one of two newly discovered antibodies that also attack the point of communication between nerves and muscle. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - August 19, 2020 Category: International Medicine & Public Health Source Type: news

Coronavirus: Severe cases could trigger autoimmune disease
A case report from Garibaldi Hospital in Catania, Italy, tracked three coronavirus patients who were subsequently diagnosed with myasthenia gravis one week after fever onset. (Source: the Mail online | Health)
Source: the Mail online | Health - August 17, 2020 Category: Consumer Health News Source Type: news

What Causes Myasthenia Gravis
? (Source: eMedicineHealth.com)
Source: eMedicineHealth.com - May 22, 2020 Category: General Medicine Source Type: news

Rituximab Promising in New-Onset Myasthenia Gravis Rituximab Promising in New-Onset Myasthenia Gravis
New research suggests rituximab is safer and more effective than immunosuppressants for myasthenia gravis, especially in new-onset disease.Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - May 11, 2020 Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news

Understanding infection risks in patients with myasthenia gravis
(Source: St. Michael's Hospital News and Media)
Source: St. Michael's Hospital News and Media - February 29, 2020 Category: Hospital Management Tags: Hospital News Source Type: news

What Are the Different Types of Myasthenia Gravis?
Discussion Myasthenia gravis (MG) is a problem of the neuromuscular junction which causes muscle weakness. It can occur in all ages and have a range of symptoms from mild localized disease to mortality-threatening respiratory failure. MG occurs in 1.7-30 cases/million, with a prevalence of 77.7 cases/million. Pediatric patients comprise 10-15% of all patients with MG. In various Asian populations, the juvenile MG can be up to 50% of all of the MG cases. Fluctuations in muscle weakness is a hallmark of the disease. As a reminder, “[i]n normal synaptic transmission in the neuromuscular junction, the axon is depolarize...
Source: PediatricEducation.org - February 17, 2020 Category: Pediatrics Authors: Pediatric Education Tags: Uncategorized Source Type: news

Study identifies interaction site for serotonin type 3A and RIC-3 chaperone
(Texas Tech University Health Sciences Center) Serotonin type 3A is a member of the protein superfamily known as pentameric ligand-gated ion channels. When these channels don't function properly, these proteins have been linked to Alzheimer's disease, Parkinson's disease, epilepsy, schizophrenia, alcohol addiction and myasthenia gravis. Michaela Jansen, Pharm.D., Ph.D., from the Texas Tech University Health Sciences Center recently completed a study that provides novel insights into a protein-protein interaction that could lead to more effective treatments for these disorders. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - February 4, 2020 Category: International Medicine & Public Health Source Type: news

Drug Trial Snapshot: FIRDAPSE
Treatment of Lambert-Eaton myasthenic syndrome (LEMS) in adults. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - December 4, 2019 Category: Drugs & Pharmacology Authors: FDA Source Type: news

Diagnosis and Treatment of Myasthenia Gravis Diagnosis and Treatment of Myasthenia Gravis
Get up-to-date on the latest advancements in the diagnosis and treatment of myasthenia gravis.Current Opinion in Rheumatology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 11, 2019 Category: Consumer Health News Tags: Rheumatology Journal Article Source Type: news

Yale receives funding to study myasthenia gravis
National Institutes of Health has awarded a research team from Yale and other universities $7.8 million to establish a rare disease network called MGNet. (Source: Yale Science and Health News)
Source: Yale Science and Health News - October 17, 2019 Category: Universities & Medical Training Source Type: news

Reversion Failure of Neuromuscular Block in Myasthenia Gravis Reversion Failure of Neuromuscular Block in Myasthenia Gravis
This case report highlights the importance of cholinesterase inhibitors management and neuromuscular block monitoring in the perioperative period for patients with myasthenia gravis.BMC Anesthesiology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - October 9, 2019 Category: Consumer Health News Tags: Anesthesiology Journal Article Source Type: news

Medical News Today: The key to myasthenia gravis progression may be hidden in serum
New research finds biomarkers for myasthenia gravis, an autoimmune condition, that may help diagnose it and create individualized treatments in the future. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - September 8, 2019 Category: Consumer Health News Tags: Medical Devices / Diagnostics Source Type: news

Zilucoplan May Decrease Symptoms of Myasthenia Gravis Zilucoplan May Decrease Symptoms of Myasthenia Gravis
The novel self-administered subcutaneous agent is safe and relatively well tolerated in generalized myasthenia gravis, a new phase 2 trial and extension study report.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - May 15, 2019 Category: Consumer Health News Tags: Neurology & Neurosurgery News Source Type: news

FDA approves first treatment for children with Lambert-Eaton myasthenic syndrome
The U.S. Food and Drug Administration approved Ruzurgi (amifampridine) tablets for the treatment of Lambert-Eaton myasthenic syndrome (LEMS) in patients 6 to less than 17 years of age. This is the first FDA approval of a treatment specifically for pediatric patients with LEMS. (Source: World Pharma News)
Source: World Pharma News - May 9, 2019 Category: Pharmaceuticals Tags: Featured FDA Regulatory Affairs Source Type: news

FDA Approves Ruzurgi for Children With Rare Autoimmune Disorder
TUESDAY, May 7, 2019 -- Ruzurgi (amifampridine) tablets are now approved to treat Lambert-Eaton myasthenic syndrome (LEMS) in children aged 6 to 17 years, the U.S. Food and Drug Administration announced yesterday. Ruzurgi is the first treatment to... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - May 7, 2019 Category: Pharmaceuticals Source Type: news

FDA grants Jacobus Pharma approval for rare disease drug
Jacobus Pharmaceutical Co Inc on Monday won U.S. approval for the first drug to treat children with Lambert-Eaton myasthenic syndrome, a rare autoimmune disorder. (Source: Reuters: Health)
Source: Reuters: Health - May 6, 2019 Category: Consumer Health News Tags: healthNews Source Type: news

FDA Approves Ruzurgi (amifampridine) for Children with Lambert-Eaton Myasthenic Syndrome
May 06, 2019 -- The U.S. Food and Drug Administration today approved Ruzurgi (amifampridine) tablets for the treatment of Lambert-Eaton myasthenic syndrome (LEMS) in patients 6 years to less than 17 years of age. This is the first FDA approval of a... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - May 6, 2019 Category: Drugs & Pharmacology Source Type: news

Updates in Parkinson's, Myasthenia Gravis, and Multiple Sclerosis Updates in Parkinson's, Myasthenia Gravis, and Multiple Sclerosis
New studies in neurology: Dr Christoph Diener discusses recent developments in the field.Medscape Neurology (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - March 21, 2019 Category: Neurology Tags: Neurology & Neurosurgery Commentary Source Type: news

Coral Gables drug company under fire for drug pricing says patient care is 'top priority'
Coral Gables-based Catalyst Pharmaceuticals said patient care is its "top priority" after Sen. Bernie Sanders, I-Vermont, criticized the firm for its pricing of a medication that treats a rare autoimmune disorder. "Catalyst’s top priority is improving patient care in the [Lambert-Eaton Myasthenic Syndrome] community and potentially elsewhere within the neuromuscular community," Catalyst said in a statement provided to the South Florida Business Journal. "We will respond to Senator Sanders’… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - February 6, 2019 Category: American Health Authors: Ashley Portero Source Type: news

Thymectomy Improves Outcomes in Non-Thymomatous Myasthenia Gravis Thymectomy Improves Outcomes in Non-Thymomatous Myasthenia Gravis
Thymectomy plus prednisone improves outcomes in patients with non-thymomatous myasthenia gravis (MG), compared with prednisone alone, according to results from the two-year extension of the MGTX randomized trial.Reuters Health Information (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - February 6, 2019 Category: Allergy & Immunology Tags: Neurology & Neurosurgery News Source Type: news

Thymectomy & #43; PDN Beneficial for Non-Thymomatous Myasthenia Gravis
WEDNESDAY, Jan. 30, 2019 -- For patients with non-thymomatous myasthenia gravis, thymectomy plus prednisone confers benefits versus prednisone alone at five years, according to a study published online Jan. 25 in The Lancet Neurology. Gil I. Wolfe,... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - January 30, 2019 Category: Pharmaceuticals Source Type: news

When You ’ re Struggling with Self-Loathing in Bipolar Disorder
Many people with bipolar disorder struggle with self-loathing. Maybe the self-loathing starts as the depressive phase does with all sorts of awful thoughts about yourself. Because that’s how depression works: It outright lies, and inflicts pain. You can’t do anything right. You’re an abject failure. You’re also stupid. And worthless, and no one will ever really love you for you. You are not attractive or thin or strong enough. You are weak, and you are an embarrassment. Maybe it happens after a manic or hypomanic episode, because you feel terrible about what you did or said during th...
Source: Psych Central - December 2, 2018 Category: Psychiatry Authors: Margarita Tartakovsky, M.S. Tags: Bipolar Disorders General Self-Esteem Self-Help Autoimmune Disease Bipolar Disorder Mood Disorder Negative Thoughts Self Hatred Self Loathing Source Type: news

FDA OKs First Treatment for Lambert-Eaton Myasthenic Syndrome FDA OKs First Treatment for Lambert-Eaton Myasthenic Syndrome
Amifampridine (Firdapse) is approved for adults with Lambert-Eaton myasthenic syndrome, a rare autoimmune disorder characterized by muscle weakness.FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 30, 2018 Category: Consumer Health News Tags: Neurology & Neurosurgery News Alert Source Type: news

FDA approves first treatment for Lambert-Eaton myasthenic syndrome, a rare autoimmune disorder
The U.S. Food and Drug Administration today approved Firdapse (amifampridine) tablets for the treatment of Lambert-Eaton myasthenic syndrome (LEMS) in adults. LEMS is a rare autoimmune disorder that affects the connection between nerves and muscles and causes weakness and other symptoms in affected patients. This is the first FDA approval of a treatment for LEMS. (Source: World Pharma News)
Source: World Pharma News - November 30, 2018 Category: Pharmaceuticals Tags: Featured FDA Regulatory Affairs Source Type: news

Immune checkpoints could be key to treating autoimmune disease myasthenia gravis
(Kanazawa University) The PD-1 immune checkpoint is essential for self-recognition by the immune system, with disruption of the pathway associated with several autoimmune disorders. However, the involvement of PD-1 and its ligand PD-L1 in muscle-weakening autoimmune disease myasthenia gravis is unclear. Now, researchers at Kanazawa University have linked increased PD-L1 expression in the muscles of myasthenia gravis patients with disease severity and shown that this could ultimately help control the immune response and modulate disease symptoms. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - November 30, 2018 Category: International Medicine & Public Health Source Type: news

FDA Approves Firdapse for Rare Autoimmune Disorder
First agency - sanctioned treatment for adults with Lambert - Eaton myasthenic syndrome (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - November 30, 2018 Category: Cancer & Oncology Tags: Neurology, Oncology, Pharmacy, Institutional, Source Type: news

FDA Approves Firdapse for Rare Autoimmune Disorder
THURSDAY, Nov. 29, 2018 -- Firdapse (amifampridine) tablets have been approved by the U.S. Food and Drug Administration for adults with Lambert-Eaton myasthenic syndrome (LEMS). The drug is the first agency-sanctioned treatment for the autoimmune... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - November 29, 2018 Category: Pharmaceuticals Source Type: news

FDA approves new drug developed by Coral Gables company
The U.S. Food and Drug Administration has approved Firdapse, a new medicine developed by Coral Gables-based Catalyst Pharmaceuticals. The biopharmaceutical company (Nasdaq: CPRX) expects the drug to be commercially available in the first quarter of 2019. It was designed to treat Lambert-Eaton Myasthenic Syndrome, a rare autoimmune disease that causes muscle weakness and fatigue. "The approval of Firdapse is a crowning achieveme nt for our company and an important step forward in our transition into… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - November 29, 2018 Category: Biotechnology Authors: Emon Reiser Source Type: news

Firdapse (Amifampridine) Approved for Rare Autoimmune Disorder
THURSDAY, Nov. 29, 2018 -- Firdapse (amifampridine) tablets have been approved by the U.S. Food and Drug Administration for adults with Lambert-Eaton myasthenic syndrome (LEMS). It's the first agency-sanctioned treatment for the autoimmune disease... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - November 29, 2018 Category: General Medicine Source Type: news

FDA Approves Firdapse (amifampridine) for Lambert-Eaton Myasthenic Syndrome
November 28, 2018 -- The U.S. Food and Drug Administration today approved Firdapse (amifampridine) tablets for the treatment of Lambert-Eaton myasthenic syndrome (LEMS) in adults. LEMS is a rare autoimmune disorder that affects the connection... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - November 28, 2018 Category: Drugs & Pharmacology Source Type: news

FDA approves first treatment for Lambert-Eaton myasthenic syndrome, a rare autoimmune disorder
FDA approved Firdapse (amifampridine) tablets for the treatment of Lambert-Eaton myasthenic syndrome (LEMS) in adults. LEMS is a rare autoimmune disorder. This is the first FDA approval of a treatment for LEMS. (Source: Food and Drug Administration)
Source: Food and Drug Administration - November 28, 2018 Category: American Health Source Type: news

Catalyst Pharmaceuticals files new drug application with FDA
Catalyst Pharmaceuticals has submitted a new drug application (NDA) to the U.S. Food and Drug Administration, bringing the Coral Gables-based drug maker one step closer to launching Firdapse, a treatment for a rare degenerative neuromuscular disease. Founded in 2002, Catalyst (Nasdaq: CPRX) has been working to develop Firdapse for almost a decade, a common timeline in the highly regulated pharmaceutical industry. Firdapse aims to treats symptoms of Lambert-Eaton myasthenic syndrome, a degenerative… (Source: bizjournals.com Health Care News Headlines)
Source: bizjournals.com Health Care News Headlines - March 29, 2018 Category: Health Management Authors: Debora Lima Source Type: news

Catalyst Pharmaceuticals Announces Submission of New Drug Application for Firdapse for Treatment of Lambert-Eaton Myasthenic Syndrome
CORAL GABLES, Fla., March 29, 2018 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular... (Source: Drugs.com - New Drug Applications)
Source: Drugs.com - New Drug Applications - March 29, 2018 Category: Drugs & Pharmacology Source Type: news

What is the Besinger Score?
Discussion Myasthenia gravis (MG) is a rare disease in the pediatric population. The incidence depends on the population studied but is estimated at 1-9/1 million/year. It was first described by William Heinrich Erb in 1879. The cause is autoantibodies against components of the post-synaptic membrane of the neuromuscular junction, usually against the acetylcholine binding receptor (AChR). It can occur at any age but is more common in the adult population. Juvenile patients (0-19 years) are divided into prepubertal (12 years) who have disease presentations similar to the adult population. In adults there are 5 grades: ocula...
Source: PediatricEducation.org - February 19, 2018 Category: Pediatrics Authors: pediatriceducationmin Tags: Uncategorized Source Type: news

Pyridostigmine treatment reverses pediatric complications of botulinum toxin therapy
(Medical University of South Carolina) In an article published online ahead of print by The Journal of Pediatrics, physicians at the Medical University of South Carolina report that complications from botox therapy for nerve disorders can be reversed with pyridostigmine, a common treatment for myasthenia gravis. The report is the first such use in pediatric patients. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - January 26, 2018 Category: International Medicine & Public Health Source Type: news

FDA Approves Soliris (eculizumab) for the Treatment of Patients with Generalized Myasthenia Gravis (GMG)
NEW HAVEN, Conn.--(BUSINESS WIRE) October 23, 2017 --Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) announced today that the U.S. Food and Drug Administration (FDA) has approved Soliris (eculizumab) as a treatment for adult patients with generalized... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - October 23, 2017 Category: Drugs & Pharmacology Source Type: news

Study explains why myasthenia patients relapse after treatment
A new Yale-led study helps explain why some myasthenia gravis (MG) patients relapse after initially responding to a drug called rituximab. (Source: Yale Science and Health News)
Source: Yale Science and Health News - September 7, 2017 Category: Universities & Medical Training Source Type: news

Scientists make first crystal model of under-diagnosed autoimmune disease
(University of Southern California) Doctors are limited in how they can treat patients with myasthenia gravis, an autoimmune disease, to just treating its symptoms. The creation of a crystal model gives scientists new insight into a possible target for drug therapy development. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - June 12, 2017 Category: Biology Source Type: news

Disease Awareness Months Work, Even If You Don't Wear The Ribbon
June ​is the month for more than 10 disease-related awareness campaigns, including Myasthenia Gravis Awareness Month, National Congenital Cytomegalovirus Awareness Month and National Scleroderma Awareness Month. It also hosts a handful of awareness weeks and days, ranging from Helen Keller Deaf-Blind Awareness Week to World Sickle Cell Day. June’s awareness list is shorter than most, but every month is full of diseases and disorders to take note of. You probably haven’t heard of half of them, and you’re not alone. So what’s the point of an awareness day, week or month? To understand the chall...
Source: Healthy Living - The Huffington Post - June 2, 2017 Category: Consumer Health News Source Type: news